Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages):

	Three Months Ended March 31,
Net sales	2021			2020
MedSurg	$	860		$	774
Rhythm and Neuro	750			703
Cardiovascular	1,129			1,026
Total net sales of reportable segments	2,739			2,502
All other (Specialty Pharmaceuticals)(1)	13			41
Consolidated net sales	$	2,752		$	2,543
	Three Months Ended March 31,
Income (loss) before income taxes	2021			2020
MedSurg	$	332		$	259
Rhythm and Neuro	148			99
Cardiovascular	338			199
Total operating income of reportable segments	819			556
All other (Specialty Pharmaceuticals)(1)	4			26
Unallocated amounts:
Corporate expenses, including hedging activities	(153)			(33)
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs	(114)			(202)
Amortization expense	(185)			(201)
Operating income (loss)	370			146
Other expense, net	(45)			(124)
Income (loss) before income taxes	$	325		$	22
(1) On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales and income (loss) before income taxes for the first quarter of 2021 include Specialty Pharmaceuticals up to the date of the closing of the transaction.
Operating income of reportable segments as a percentage of net sales of reportable segments	Three Months Ended March 31,
	2021			2020
MedSurg	38.6		%	33.4		%
Rhythm and Neuro	19.7		%	14.1		%
Cardiovascular	30.0		%	19.4		%